Testing pembrolizumab after CYAD-101 plus FOLFOX in colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This early-phase study tests whether adding pembrolizumab after CYAD-101 and FOLFOX chemotherapy can help treat metastatic colon or rectal cancer. It is mainly looking for safety and signs of how well the treatment works in people whose cancer has not responded to prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your colon or rectal cancer has spread (metastatic) and cannot be removed by surgery
- Your tumor is not MSI-H; it is mismatch-repair proficient (pMMR)
- Your cancer has a measurable spot the doctors can track on scans
- Your cancer has come back or grown after at least one treatment that included FOLFOX, and you are scheduled to get FOLFOX
- You had no more than mild nerve side effects (up to grade 1) from your last chemo
- You can do daily activities fairly well (ECOG 0 or 1), and you can have a new tumor biopsy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests CYAD-101, an immune-cell treatment made from donor T-cells, given with standard chemotherapy. It is for people with colon or rectal cancer that has spread and has not responded to prior treatments.
This trial tests a new immunotherapy drug (STC-1010) for people with colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the drug can shrink tumors or slow the disease.
This trial tests a new drug (VVD-133214) combined with an existing immunotherapy (pembrolizumab) for advanced colorectal cancer that is mismatch repair deficient. It aims to see if the combination works better than pembrolizumab alone in shrinking or controlling the cancer.
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
This trial tests two immunotherapy drugs (ADG126 and pembrolizumab) given before surgery for locally advanced colorectal cancer that hasn't spread. It aims to shrink tumors and improve outcomes.
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
Hear when a new Unresectable Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.